NASDAQ:SOPH SOPHiA GENETICS (SOPH) Stock Forecast, Price & News $2.44 +0.03 (+1.24%) (As of 11:31 AM ET) Add Compare Share Share Today's Range$2.41▼$2.5250-Day Range$2.30▼$4.2752-Week Range$1.68▼$5.77Volume1,664 shsAverage Volume84,560 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$6.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media SOPHiA GENETICS MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside153.3% Upside$6.33 Price TargetShort InterestHealthy0.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.20) to ($0.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.72 out of 5 stars 3.3 Analyst's Opinion Consensus RatingSOPHiA GENETICS has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.33, SOPHiA GENETICS has a forecasted upside of 153.3% from its current price of $2.50.Amount of Analyst CoverageSOPHiA GENETICS has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.06% of the float of SOPHiA GENETICS has been sold short.Short Interest Ratio / Days to CoverSOPHiA GENETICS has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SOPHiA GENETICS has recently increased by 1.09%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSOPHiA GENETICS does not currently pay a dividend.Dividend GrowthSOPHiA GENETICS does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SOPH. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for SOPHiA GENETICS this week, compared to 2 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SOPHiA GENETICS insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.88% of the stock of SOPHiA GENETICS is held by insiders.Percentage Held by InstitutionsOnly 36.68% of the stock of SOPHiA GENETICS is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for SOPHiA GENETICS are expected to grow in the coming year, from ($1.20) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SOPHiA GENETICS is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SOPHiA GENETICS is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSOPHiA GENETICS has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About SOPHiA GENETICS (NASDAQ:SOPH) StockSOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharma customers worldwide. The company was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.Read More SOPH Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SOPH Stock News HeadlinesSeptember 26, 2023 | americanbankingnews.comSOPHiA GENETICS (NASDAQ:SOPH) Stock Price Up 5%September 20, 2023 | americanbankingnews.comSOPHiA GENETICS (NASDAQ:SOPH) vs. Ignyte Acquisition (NASDAQ:IGNY) Financial ReviewSeptember 26, 2023 | UNKNOWN (Ad)Bringing Space Down to EarthCutting edge, AI-powered, Space-based Earth-observation solutionsSeptember 13, 2023 | finance.yahoo.comLaboratorio Curie Expands Relationship with SOPHiA GENETICSSeptember 8, 2023 | msn.comItaly’s IRCCS IRST goes live on SOPHiA GENETICS platformSeptember 7, 2023 | finance.yahoo.comSOPHiA GENETICS Announces the IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) is Live on the SOPHiA DDM™ PlatformAugust 31, 2023 | msn.comCHU Bordeaux deploys SOPHiA DDM Platform to support cancer researchAugust 30, 2023 | finance.yahoo.comCHU Bordeaux is live on SOPHiA GENETICSSeptember 26, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...August 23, 2023 | msn.comGustave Roussy, SOPHiA expand alliance on cancer treatmentAugust 22, 2023 | finance.yahoo.comSOPHiA GENETICS Expands Relationship with Gustave RoussyAugust 18, 2023 | marketwatch.comSophia Genetics Up 11% as Italian Hospital Expands Platform UsageAugust 17, 2023 | fool.comSOPHiA Genetics (NASDAQ: SOPH)August 17, 2023 | finance.yahoo.comA.O.U. San Giovanni di Dio Ruggi d'Aragona Expands Usage of SOPHiA GENETICS DDM™ PlatformAugust 12, 2023 | markets.businessinsider.comJ.P. Morgan Remains a Buy on SOPHiA GENETICS (SOPH)August 9, 2023 | msn.comTulane University taps SOPHiA GENETICS for blood cancer researchAugust 8, 2023 | finance.yahoo.comSOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Misses Revenue EstimatesAugust 8, 2023 | benzinga.comA Preview Of Sophia Genetics's EarningsAugust 8, 2023 | markets.businessinsider.comSOPHiA GENETICS SA earnings preview: what Wall Street is expectingAugust 8, 2023 | msn.comSOPHiA Genetics GAAP EPS of -$0.33 misses by $0.02, revenue of $15.1M misses by $0.14MAugust 8, 2023 | finance.yahoo.comTulane University School of Medicine Uses SOPHiA GENETICS to Advance Research of Blood CancersAugust 8, 2023 | finance.yahoo.comSOPHiA GENETICS Reports Financial Results for the Second Quarter of Fiscal 2023July 30, 2023 | finanznachrichten.deSOPHiA GENETICS' SOPHiA DDM HRD Solution is Tapped by Unipath Specialty Laboratory LimitedJuly 25, 2023 | finance.yahoo.comSOPHiA GENETICS to Announce Financial Results for the Second Quarter of Fiscal 2023 on August 8, 2023July 13, 2023 | finance.yahoo.comSOPHiA GENETICS Announces Gruppo Centro Servizi Medici (CSM) is Live on the SOPHiA DDM™ PlatformJuly 7, 2023 | finance.yahoo.comCentre Hospitalier de Bastia is Live on SOPHiA GENETICSJuly 2, 2023 | finance.yahoo.comSOPHiA GENETICS (NASDAQ:SOPH) swells 17% this week, taking one-year gains to 20%See More Headlines Receive SOPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SOPHiA GENETICS and its competitors with MarketBeat's FREE daily newsletter. Email Address SOPH Company Calendar Last Earnings8/08/2023Today9/26/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SOPH CUSIPN/A CIK1840706 Webwww.sophiagenetics.com Phone41-21-694-1060FaxN/AEmployees466Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.33 High Stock Price Forecast$11.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+153.3%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,450,000.00 Net Margins-145.00% Pretax Margin-145.34% Return on Equity-41.11% Return on Assets-33.01% Debt Debt-to-Equity RatioN/A Current Ratio5.34 Quick Ratio5.17 Sales & Book Value Annual Sales$47.56 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.16 per share Price / Book0.79Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta1.33 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Jurgi Camblong M.B.A. (Age 45)Ph.D., Co-Founder, CEO & Director Comp: $1.11MMr. Ross Jordan Muken B.Sc. (Age 42)Exec. VP, CFO & COO Mr. Abhimanyu VermaSr. VP & CTODr. Zhenyu Xu Ph.D. (Age 40)Exec. VP & Chief Scientific Officer Katherine BailonVP of Investor RelationsMr. Daan van Well L.L.M. (Age 49)M.B.A., Exec. VP, Chief Legal Officer & Gen. Counsel Mr. Kevin PuylaertVP of Bus. Devel. & MarketingMs. Manuela Da Silva Valente B.A. (Age 52)Sr. VP & Chief People Officer Dr. Philippe Menu M.B.A. (Age 41)M.D., Ph.D., Exec. VP, Chief Medical Officer & Chief Product Officer Mr. Peter CasasantoSr. VP & Chief BioPharma OfficerMore ExecutivesKey CompetitorsAlvotechNYSE:ALVOVectivBioNASDAQ:VECT60 Degrees Pharmaceuticals, Inc. WarrantNASDAQ:SXTPWAclarionNASDAQ:ACONWAinosNASDAQ:AIMDWView All CompetitorsInstitutional OwnershipPura Vida Investments LLCSold 238,769 shares on 8/14/2023Ownership: 0.000%Credit Suisse AGSold 18,068 shares on 8/11/2023Ownership: 0.000%Geode Capital Management LLCBought 9,474 shares on 8/11/2023Ownership: 0.000%JPMorgan Chase & Co.Sold 18,604 shares on 8/11/2023Ownership: 0.000%Meitav Investment House Ltd.Bought 27,805 shares on 8/10/2023Ownership: 0.044%View All Institutional Transactions SOPH Stock - Frequently Asked Questions Should I buy or sell SOPHiA GENETICS stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SOPHiA GENETICS in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SOPH shares. View SOPH analyst ratings or view top-rated stocks. What is SOPHiA GENETICS's stock price forecast for 2023? 3 brokers have issued twelve-month target prices for SOPHiA GENETICS's shares. Their SOPH share price forecasts range from $2.00 to $11.00. On average, they expect the company's stock price to reach $6.33 in the next twelve months. This suggests a possible upside of 153.3% from the stock's current price. View analysts price targets for SOPH or view top-rated stocks among Wall Street analysts. How have SOPH shares performed in 2023? SOPHiA GENETICS's stock was trading at $2.06 at the beginning of the year. Since then, SOPH shares have increased by 21.4% and is now trading at $2.50. View the best growth stocks for 2023 here. When is SOPHiA GENETICS's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our SOPH earnings forecast. How were SOPHiA GENETICS's earnings last quarter? SOPHiA GENETICS SA (NASDAQ:SOPH) released its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $0.04. The company earned $15.05 million during the quarter, compared to analysts' expectations of $15.10 million. SOPHiA GENETICS had a negative trailing twelve-month return on equity of 41.11% and a negative net margin of 145.00%. What guidance has SOPHiA GENETICS issued on next quarter's earnings? SOPHiA GENETICS updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $61.83M-, compared to the consensus revenue estimate of $62.12 million. When did SOPHiA GENETICS IPO? (SOPH) raised $234 million in an IPO on Friday, July 23rd 2021. The company issued 13,000,000 shares at $17.00-$19.00 per share. What is SOPHiA GENETICS's stock symbol? SOPHiA GENETICS trades on the NASDAQ under the ticker symbol "SOPH." Who are SOPHiA GENETICS's major shareholders? SOPHiA GENETICS's stock is owned by many different retail and institutional investors. Top institutional shareholders include Credit Suisse AG (0.00%), Principal Financial Group Inc. (0.00%), Pura Vida Investments LLC (0.00%), Geode Capital Management LLC (0.00%), JPMorgan Chase & Co. (0.00%) and Meitav Investment House Ltd. (0.04%). How do I buy shares of SOPHiA GENETICS? Shares of SOPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is SOPHiA GENETICS's stock price today? One share of SOPH stock can currently be purchased for approximately $2.50. How many employees does SOPHiA GENETICS have? The company employs 466 workers across the globe. How can I contact SOPHiA GENETICS? The official website for the company is www.sophiagenetics.com. The company can be reached via phone at 41-21-694-1060. This page (NASDAQ:SOPH) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SOPHiA GENETICS SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.